Search
for
Sort by
Research 30 of 119
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- The PDGF/PDGFR pathway as a drug target
- Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
- Management of Toxicities of Targeted Therapies
- Rapid hair depigmentation in patient treated with pazopanib
- Forum
- Properties and use of plant stem cells in cosmetic products
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts